Dianthus Therapeutics (DNTH)

• Market cap: $4.78B
• 1 day: 0.06%
• 5 days: 0.6%
• 1 month: 3.89%
• 3 months: 65.19%
• 6 months: 158.15%
• Year to date: 121.4%
• 1 year: 304.84%
• 5 years: -52.75%
• 10 years: -62.19%
• Sector: Healthcare
• Industry: Biotechnology

About: Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Employees: 92